“Much has been said about Sanofi and its vaccine business, given that we were not one of two labs with an approved messenger RNA Covid vaccine. Let's be clear: I don't see much potential impact at this stage (…). We are perfectly positioned to play an important role in the vaccine market. ”
While Sanofi's anti-Covid vaccine is still long overdue, Paul Hudson, its CEO, has tried to change gear.
The first French laboratory, which announced almost a year ago to the day several months of delay in its clinical trials, still hopes to publish the results of the final phase of tests
"in the next few weeks".
To read also
Stéphane Bancel: "In 12 to 18 months, Moderna will have the scale of a Roche or Novartis"
If they are positive, Sanofi continues to bet on a “booster” strategy but its vaccine would only have a complementary role, at least during the pandemic phase.
"The stake for us is not financial,
insists Thomas Triomphe, at the head of the vaccines activity of Sanofi (16.5% of the turnover).
This article is for subscribers only.
You have 69% left to discover.
To cultivate one's freedom is to cultivate one's curiosity.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in
